8-K: Enovis Reports Q4, Full Year 2025 Results Amid Goodwill Impairment

Enovis Corporation announced its fourth quarter and full year 2025 financial results, reporting significant sales growth but also a substantial non-cash goodwill impairment charge.

Summary

• Full year 2025 net sales reached $2.2 billion, marking a 7% reported growth and 6% organic growth year-over-year.
• The company reported a full year net loss from continuing operations of $1,182 million, primarily due to a $1,050 million non-cash goodwill impairment charge.
• Adjusted EBITDA for the full year 2025 was $403 million, with adjusted diluted earnings per share at $3.30.
• Fourth quarter 2025 net sales were $576 million, a 3% reported and 2% organic increase from Q4 2024.
• Q4 net loss from continuing operations was $519 million, including a $501 million non-cash goodwill impairment charge.
• Adjusted EBITDA for Q4 was $112 million, and adjusted earnings per diluted share were $0.95.
• Reconstructive segment sales grew 10% reported and 8% organically for the full year, and 7% reported and 3% organically for Q4.
• Prevention & Recovery segment sales grew 4% reported and organically for the full year, and declined 1% reported (flat organically) for Q4.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While organic sales growth and 2026 guidance are positive, the substantial goodwill impairment charge significantly impacts GAAP profitability and reflects a re-evaluation of asset values, leading to a cautious outlook.

Positives

• Full year 2025 net sales grew 7% on a reported basis and 6% organically to $2.2 billion.
• Full year 2025 Reconstructive sales grew 10% year-over-year on a reported basis and 8% on an organic basis.
• Full year 2025 Prevention & Recovery sales grew 4% year-over-year on both a reported and organic basis.
• Achieved positive free cash flow and debt reduction in 2025.
• Provided a positive 2026 financial outlook with expected revenue of $2.31-2.37 billion (4-6% organic growth) and adjusted EBITDA of $425-435 million.
• Net cash provided by operating activities significantly increased to $217,293 thousand in 2025 from $113,504 thousand in 2024.

Negatives

• Reported a full year 2025 net loss from continuing operations of $1,182 million, primarily due to a $1,050 million non-cash goodwill impairment charge.
• Reported a fourth quarter 2025 net loss from continuing operations of $519 million, including a $501 million non-cash goodwill impairment charge.
• Goodwill decreased significantly from $1,692,709 thousand in 2024 to $718,299 thousand in 2025.
• Accumulated deficit increased substantially from $(283,023) thousand in 2024 to $(1,467,463) thousand in 2025.
• Prevention & Recovery net sales declined 1% on a reported basis and were flat on an organic basis in Q4 2025.

Risks

• Risks related to the integration of Lima.
• Impact of public health emergencies and global pandemics.
• Disruptions in the global economy caused by escalating geopolitical tensions, including ongoing conflicts between Russia and Ukraine and in the Middle East.
• Macroeconomic conditions, including the impact of inflationary pressures.
• Changes in government trade policies, including the implementation of tariffs.
• Supply chain disruptions.
• Increasing energy costs and availability concerns, particularly in the European market.
• Other impacts on business and ability to execute business continuity plans.

Future Outlook

Enovis expects 2026 revenue to approximate $2.31-2.37 billion, reflecting 4-6% organic revenue growth. Adjusted EBITDA is projected to be in the range of $425-435 million, with full-year adjusted earnings per share expected between $3.52 and $3.73, based on current exchange rates.

Management Comments

• Our 2025 performance reflects a year of meaningful operational progress for the Company.
• We advanced our second-year Lima integration priorities, operated effectively in a dynamic global environment, and continued to demonstrate above-market organic growth with sustainable year-over-year operating improvements which included positive free cash flow and debt reduction.
• As we enter 2026, our focus remains consistent and disciplined – driving commercial execution, advancing our rich innovation pipeline, improving operational efficiency, and maintaining financial discipline – as we position the Company for durable, capital-efficient growth while remaining attentive to the evolving macro environment.

Industry Context

StockSavvy.ai notes that Enovis's continued above-market organic growth in its Reconstructive segment, despite a challenging global environment, indicates strong product demand and effective market penetration within the orthopedics sector. The significant goodwill impairment, however, suggests a re-evaluation of past acquisitions' value in the current economic climate, a trend observed across various industries facing higher interest rates and stricter valuation metrics.

Stakeholder Impact

• Shareholders: Significant net losses due to goodwill impairment will negatively impact reported GAAP earnings per share and accumulated deficit, potentially affecting investor confidence despite positive adjusted metrics and future guidance.
• Employees: The filing mentions "payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima," indicating some workforce adjustments related to integration.
• Customers: Continued investment in innovation and focus on "clinically differentiated solutions that generate measurably better patient outcomes" suggests a positive impact on product offerings and quality.
• Creditors: Debt reduction and positive free cash flow in 2025 are favorable for creditors, indicating improved liquidity and financial management.

Next Steps

• Host an investor conference call and live webcast on February 26, 2026, at 8:30 am ET to discuss results.
• Focus for 2026 includes driving commercial execution, advancing the innovation pipeline, improving operational efficiency, and maintaining financial discipline.

Key Dates

Recommendation

While Enovis demonstrated solid organic sales growth and provided an optimistic adjusted outlook for 2026, the substantial non-cash goodwill impairment charge for 2025 is a significant concern, reflecting a material re-evaluation of asset values. This impairment, coupled with the resulting large GAAP net loss, introduces uncertainty regarding the underlying value of past acquisitions. Investors should hold to monitor the company's ability to execute on its 2026 guidance and demonstrate sustained value creation post-impairment, particularly how the market reacts to the re-valuation of its assets.

Keywords

Enovis, ENOV, Medical Technology, Orthopedics, Reconstructive, Prevention & Recovery, Financial Results, Earnings, Goodwill Impairment, SEC Filing, Q4 2025, Full Year 2025, 2026 Outlook, Adjusted EBITDA, Organic Growth, Lima Acquisition